Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAD106 in Mild Alzheimer's Disease
NCT00733863Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2008
- Primary completion
- Feb 2010
- Modality
- Recombinant Protein Vaccines, Peptide-based Cancer Vaccines
- Countries
- 4
01
Overview
A Phase 2 trial of amilomotide in Alzheimer's disease (AD), sponsored by Novartis. Started Jul 2008; status: completed.
02
Drugs
amilomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00733863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00733863.